ReviewJournal of medical ultrasonics (2001)2021
Attenuation coefficient (ATT) measurement for liver fat quantification in chronic liver disease.
Review in Journal of medical ultrasonics (2001), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 15 citations in OpenAlex.
- Ultrasound-derived fat fraction and automated point shear-wave elastography in diagnosing intrahepatic cholestasis of pregnancy and preeclampsia.BMC pregnancy and childbirth · 2026Article
- Accurate and spatially stable quantification of hepatic steatosis using ultrasound-derived fat fraction in metabolic dysfunction-associated steatotic liver disease (MASLD): a prospective magnetic resonance imaging-proton density fat fraction (MRI-PDFF) study.Quantitative imaging in medicine and surgery · 2026Article
- Compensated Advanced Chronic Liver Disease and Steatosis in Patients with Type 2 Diabetes as Assessed through Shear Wave Measurements and Attenuation Measurements.Biomedicines · 2024Article
- Detecting advanced liver fibrosis using ultrasound shear wave velocity measurement in the general population.Quantitative imaging in medicine and surgery · 2023Article
- Elastography of the Liver in Wilson's Disease.Diagnostics (Basel, Switzerland) · 2023Review
- Non-invasive evaluation of liver steatosis with imaging modalities: New techniques and applications.World journal of gastroenterology · 2023Review
- Application of attenuation coefficient in the assessment of hepatic involvement in children and adolescents with Wilson's disease.BMC medical imaging · 2023Article
- Ultrasound Methods for the Assessment of Liver Steatosis: A Critical Appraisal.Diagnostics (Basel, Switzerland) · 2022Review
- Feasibility of Ultrasound Attenuation Imaging for Assessing Pediatric Hepatic Steatosis.Biology · 2022Article
- Noninvasive assessment of liver fibrosis and its clinical significance in nonalcoholic fatty liver disease.Hepatology research : the official journal of the Japan Society of Hepatology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Liver fat is one of the main clinical features in chronic liver disease, and the number of fatty liver patients is increasing as the prevalence of obesity and metabolic syndrome increases globally. Noninvasive and quantitative assessment of liver fat content was made possible by recent technological advances. Attenuation coefficient (ATT) measurement is a noninvasive and quantitative liver fat measurement method used in clinical practice. The ATT value is significantly associated with histological steatosis grade. The diagnostic accuracy of ATT for histological steatosis grade is equivalent to controlled attenuation parameter (CAP), and ATT has a lower measurement failure rate than CAP because ATT can be measured on a B-mode image with the exact location of the region of interest. Furthermore, ATT measurement has high interobserver reproducibility. Since ATT measurement and other ultrasound-based modalities for liver fat quantification are easy to perform and inexpensive, these modalities are suitable for point-of-care and screening. Although emerging data suggest that quantitative liver fat content and its changes over time may be associated with disease progression in nonalcoholic fatty liver disease, the association between ATT and disease progression has not been evaluated yet. Therefore, further investigation and validation studies are necessary to strengthen the clinical significance of ATT measurement in chronic liver disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.